BCM
AVIR icon

BML Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

BML Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3M Sell
6,952,330
-106,327
-2% -$529K 18.36% 2
2026
Q1 		$38M Sell
7,058,657
-431,343
-6% -$1.98M 24.38% 2
2025
Q4 		$26.7M Buy
7,490,000
+16,037
+0.2% +$51K 23.11% 2
2025
Q3 		$21.7M Sell
7,473,963
-135,849
-2% -$464K 19.85% 2
2025
Q2 		$27.4M Hold
7,609,812
– – 20.73% 1
2025
Q1 		$22.8M Buy
7,609,812
+1,500
+0% +$4.68K 18.41% 1
2024
Q4 		$25.5M Buy
7,608,312
+958,312
+14% +$3.18M 15.83% 3
2024
Q3 		$22.3M Buy
6,650,000
+274,379
+4% +$995K 13.11% 3
2024
Q2 		$21.1M Buy
6,375,621
+838,911
+15% +$3.13M 15.06% 2
2024
Q1 		$22.4M Buy
5,536,710
+74,631
+1% +$292K 14.75% 2
2023
Q4 		$16.7M Buy
5,462,079
+662,079
+14% +$2.01M 12.62% 3
2023
Q3 		$14.4M Buy
4,800,000
+2,563,761
+115% +$8.72M 13.22% 3
2023
Q2 		$8.36M Buy
+2,236,239
New +$8.37M 7.52% 4

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BML Capital Management's AVIR Position: Q2 2026 in Review

BML Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 1.5% in Q2 2026, selling an estimated $529K and leaving 6,952,330 shares worth $32.3M. The position accounts for 18.36% of the portfolio, ranked #2.

BML Capital Management first reported a position in AVIR in Q2 2023 and has held it in 13 quarters since. The position peaked at $38M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • BML Capital Management held 6,952,330 shares of Atea Pharmaceuticals worth $32.3M as of Q2 2026.
  • BML Capital Management sold 106,327 Atea Pharmaceuticals shares in Q2 2026, an estimated $529K.
  • Atea Pharmaceuticals made up 18.36% of BML Capital Management's portfolio in Q2 2026, its #2 holding.
  • BML Capital Management first reported a position in Atea Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • BML Capital Management's Atea Pharmaceuticals position peaked at $38M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.